We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Inc4.1

Inclisiran (Leqvio) Research

Mostly mechanism / observational

52 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Inclisiran (Leqvio) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2017–2026 with a typical study size of 3,660 participants.

Based on 52 studies · 17 meta-analyses · 29 RCTs · 4,042 total participants

Confidence

High confidence

By outcome

LDL cholesterol & lipidsSustained ~48-52% LDL-C reduction maintained over 4 years with twice-yearly dosing (a CV-risk-factor benefit) · Weeks to months; sustained
Mostly mechanism / observational31 studies
Cardiovascular outcomes (pending)Sustained ~48-52% LDL-C reduction maintained over 4 years with twice-yearly dosing (a CV-risk-factor benefit) · Weeks to months; sustained
Mostly mechanism / observational14 studies
Cardiometabolic lipid control
Mostly mechanism / observational3 studies
Safety profile
Too few graded studies1 study

Active research area

40 studies in the last 5 years · Latest meta-analysis: 2026

20172026

1Meta-Analysis2023

Cowart K, Singleton J, Carris NW · Clin Ther (2023)

Inclisiran (Leqvio) Research

Mostly mechanism / observational

Inclisiran for the Treatment of Hyperlipidemia and for Atherosclerotic Cardiovascular Disease Risk Reduction: A Narrative Review.

Efficacy of Inclisiran in Patients Having Familial Hypercholesterolemia: Heterozygous Compared to Homozygous Trait, a Systematic Review and Meta-analysis.

Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta-Analysis of Randomised Controlled Trials.

A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.

The Impact of Inclisiran on Lipid Profiles in Adults with Hyperlipidemia: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials.

Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta-analysis.

Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis.

Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials.

A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran.

Inclisiran Treatment for Cardiovascular Disease Risk Reduction: A Systematic Review and Meta-Analysis.

Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management.

Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.

A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran.

Serious Adverse Events of Inclisiran in Patients With Hypercholesterolemia, a Meta-Analysis of ORION Trials.

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews.

Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.

Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis.

Efficacy and Safety of Inclisiran-An Assessment of the Consistency Between Randomized Controlled Trials and Real-World Evidence: A Systematic Review.

Trends and hotspots in familial hypercholesterolemia: A bibliometric systematic review from 2002 to 2022.

Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials.